AtaGenix Laboratories
Release time: 2025-09-02 View volume: 21
Recent market analyses estimate the antibody discovery market at USD 1.9 billion (2024) with growth to USD 3.3 billion by 2030—a compound annual growth rate (CAGR) of about 9.8%. Momentum is driven by strong pipelines in monoclonal antibodies, rapid uptake of bispecifics, and accelerated investment in antibody–drug conjugates (ADCs).
Segment | Trend |
---|---|
Monoclonal Antibodies (mAbs) | Stable growth; new targets & next-gen formats sustain demand |
Bispecific Antibodies | Fastest growth; oncology & immunology pipelines expanding |
ADCs | Strong momentum; improved linkers/payloads & targeted indications |
Approach | Notes |
---|---|
Single B-cell | Rapid hit-to-lead; native pairing preserves function |
Phage/Yeast Display | Large library diversity; efficient panning & optimization |
Hybridoma | Reliable for animal immunization routes & reagent antibodies |
In-silico/AI | Design/triage for affinity, specificity, and developability |
Region | Outlook |
---|---|
North America | Largest share; robust venture & clinical activity |
Europe | Strong academia–industry networks; CDMO capacity expanding |
Asia-Pacific | Fastest growth; investment in discovery platforms and ADC pipelines |
Note: Figures (USD 1.9B in 2024; USD 3.3B in 2030; ~9.8% CAGR) reflect aggregated estimates from the sources above; methodologies may differ among publishers.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan